Targeting cancer with epi-drugs: A precision medicine perspective

Lisa Gherardini, Ankush Sharma, Enrico Capobianco, Caterina Cinti

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Recent pan-cancer studies have shown the importance of coupling DNA methylation patterns with transcriptome profiles to reveal tumor subgroups with clinically relevant distinct characteristics. While the coupling patterns remain in most cases matter for further study and/or interpretation, it is emerging that all associations between epigenetic changes and specific cancer histotypes can facilitate the development of novel epidrugs. In particular, together with chemotherapy and chemoprevention of cancer, these epidrugs will target specific enzymes involved in the complex regulation of gene expression. This perspective surveys recent cancer epigenetic findings on target drugs and therapeutic strategies, and focuses on the epigenetic modifications that can reverse a stable differentiated state of adult cell towards neoplastic phenotypes. The relevance of such developments may thus pave the way for patient’s customized personalized therapies.

Original languageEnglish (US)
Pages (from-to)856-865
Number of pages10
JournalCurrent Pharmaceutical Biotechnology
Issue number10
StatePublished - Aug 1 2016


  • Cancer epigenomics
  • Cancer therapy
  • Epi-drugs
  • Epigenetic memory
  • Precision medicine
  • Translational medicine

ASJC Scopus subject areas

  • Biotechnology
  • Pharmaceutical Science


Dive into the research topics of 'Targeting cancer with epi-drugs: A precision medicine perspective'. Together they form a unique fingerprint.

Cite this